AMG 139

DRUG2 trials

Sponsors

AstraZeneca

Conditions

Crohn's DiseasePsoriasis

Phase 1

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 139 in Healthy Subjects and Subjects With Moderate to Severe Psoriasis

CompletedNCT01094093

AstraZenecaPsoriasis

Start: 2010-04-11End: 2011-07-26Updated: 2021-05-10

Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease Subjects

CompletedNCT01258205

AstraZenecaCrohn's Disease

Start: 2011-02-28End: 2015-02-18Updated: 2021-05-10